Corbus Pharmaceuticals Holdings (CRBP) Common Equity (2013 - 2025)

Corbus Pharmaceuticals Holdings' Common Equity history runs 13 years deep, the most recent figure standing at $147.5 million for Q4 2025.

• In Q4 2025, Common Equity rose 3.56% year-over-year to $147.5 million; the TTM figure through Dec 2025 stood at $147.5 million (up 3.56% YoY), while the FY2025 annual figure was $147.5 million, up 3.56% from the prior year.
• Common Equity was $147.5 million for Q4 2025 at Corbus Pharmaceuticals Holdings, up from $92.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $150.5 million in Q3 2024 to a low of -$6.9 million in Q4 2023.
• Historically, Common Equity has averaged $75.7 million across 5 years, with a median of $77.3 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Common Equity sank 120.93% in 2023, then jumped 48136.54% in 2024.
• A 5-year view of Common Equity shows it stood at $69.1 million in 2021, then slumped by 52.26% to $33.0 million in 2022, then slumped by 120.93% to -$6.9 million in 2023, then jumped by 2162.68% to $142.4 million in 2024, then grew by 3.56% to $147.5 million in 2025.
• The last three Common Equity figures came in at $147.5 million (Q4 2025), $92.1 million (Q3 2025), and $111.0 million (Q2 2025), per Business Quant data.